PATENT CLAIM ANALYSIS

Application Number: 16202482
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-04
Patent Classification: ["424", "204100"]

Abstract:
The present technology is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.

Claim (Index 22):
The method according to  claim 21 , wherein said identified constituent T cell epitopes engage either regulatory T cells or fail to engage effector T cells.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 98.0
- Lexical Diversity: 1.20513
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15571040', '15536857', '11802106', '14910136', '12096322']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7660265333651911
- 35 USC 102 Novelty (BERT): 0.5717743131396448
- Combined Prediction Score: 0.7466013113426365
- Mean Citation Score: 380.66167
- Max Citation Score: 640.5353
- Similarity Product: 329.92862444227336

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test